Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. We have a commercial product, Sympazan® (clobazam), and a late-stage proprietary product pipeline focused on advancing treatments for CNS diseases, as well as early-stage investigational assets that may replace invasively-administered standard of care therapies. Aquestive also collaborates with pharmaceutical partners to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®.

For recent news and press releases

Stock information

In July 2018, the Company closed an IPO and began trading on the Nasdaq® Global Market under ticker symbol “AQST”.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds